Science and Technology

Amprion Sheds Light on the Detection of Neurodegenerative Diseases With Groundbreaking Assays at AD/PD™ 2024

SAN DIEGO, March 4, 2024 /PRNewswire/ -- In a significant advancement for neurodegenerative disease diagnostics, Amprion has proudly announced its participation in the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal, from March 5 to March 9. At the conference, Amprion will present the successful application of its novel αSyn seed amplification assay (αS-SAA), the SYNTap® Biomarker Test, in numerous studies, with 10 posters and oral presentations showcasing the findings.

"We are excited to share with the international community the global research findings that contribute to the accurate diagnosis of neurological disorders enabled by our αSyn seed amplification assay," stated Russell Lebovitz, MD, Ph.D., CEO & Cofounder of Amprion. "The forum provided by AD/PD™ is an invaluable opportunity to discuss the positive impact that αS-SAA has on enhancing the detection and treatment of neurodegenerative diseases. Additionally, we are expanding our team to include diagnostics service consultants, aiming to better meet clinical needs in the United States and support researchers as well as biopharmaceutical companies in creating crucial medications for patients affected by these debilitating conditions."

The details of the posters and oral presentations focusing on the SYNTap® will highlight the assay's instrumental role in advancing our understanding of neurodegenerative diseases:

Poster Sessions:

During the first shift, running from March 6-7, three posters will be presented:

• 0488: The University of Perugia's Giovanni Bellomo, Ph.D., will discuss the investigation of Alpha-synuclein co-pathology in Alzheimer’s Disease through the cerebrospinal fluid alpha-synuclein seed amplification assay.

• 0490: Luis Concha-Marambio, Ph.D., representing Amprion, will present on the stratification of subjects with Parkinson's and Multiple System Atrophy using the semi-quantitative alpha-synuclein seed amplification assay.

• 0493: The University of Gothenburg's Bárbara Fernandes Gomes will elaborate on the optimized seed amplification assay (SAA) method as a diagnostic tool for parkinsonian disorders.

The second shift from March 8-9 will include:

• 0472: Mary Xylaki, Ph.D., from the University Medical Center Göttingen, will reveal pathological Alpha-synuclein profiling in nasal specimens of Parkinson's Disease patients.

• 0582: Ken Marek, MD, from the Institute for Neurodegenerative Disorders, will provide evidence for Alpha-Synuclein aggregation in older individuals with Hyposmia and its potential as a biomarker signature for Parkinson Disease.

Oral Presentations:

Alpha – Synuclein, Aggregation, Misfolding, and Seeding

The session on March 6, 2024, consists of two significant lectures:

• Duygu Tosun, Ph.D., from the University of California - San Francisco, will discuss Alpha-Synuclein Seed Amplification Assay (SAA) performance in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort, highlighting extensive co-morbid Lewy Body Pathology.

• Andrew Siderowf, MD MS, from the University of Pennsylvania, will investigate the association of Alpha-Synuclein Seed Amplification Assay results and Hyposmia in Parkinson's Disease and Healthy Controls.

α-Synucleinopathies: Mechanisms, Pathophysiology, and Modelling of Progression

Scheduled on March 9, 2024, attendees can look forward to insights from:

• Tanya Simuni, MD, Northwestern University, who will introduce a Biological Definition and Research Integrated Staging System of Neuronal α-Synuclein Disease in the PPMI Cohort.

PD and PSP: Advances in Diagnosis and Drug Development

On March 6, 2024, the session includes:

• Jean-Cosme Dodart, Ph.D., Vaxxinity, will showcase evidence of target engagement in a Phase 1 Clinical Trial of UB-312 for Parkinson's Disease.

"The data on the ADNI cohort presented at AD/PD™ will emphasize the utility of α-synuclein CSF SAA as a robust assay for detecting co-morbid Lewy Body pathology. It also underlines the capability to identify the co-pathology that is often hard to spot," added Mike Weiner, MD, and principal investigator for the Alzheimer's Disease Neuroimaging Initiative. "We trust that these findings can substantially enhance the accuracy of diagnoses, paving the way for the development of precision medicines for these complex neurodegenerative disorders."

An additional study that employs Amprion’s αS-SAA will be presented by Biogen, providing insight into the distribution of Alpha-Synuclein co-pathology in clinical trial cohorts with MCI, mild Alzheimer's Disease, and Progressive Supranuclear Palsy. Kyle B. Fraser, Ph.D., from Biogen Inc., will detail the findings on March 8, 2024.

Visitors who wish to understand how the SYNTap® Biomarker Test serves as an integral component in completing the neurodegenerative disease diagnostic landscape are encouraged to visit Booth #62 for more information.

About SYNTap®:

The SYNTap Biomarker Test, developed by Amprion, represents a pioneering qualitative Laboratory Developed Test (LDT), the only seed amplification assay of its kind aiding the diagnosis of synucleinopathies like Parkinson's Disease (PD), Lewy Body Dementia (LBD/DLB), and Alzheimer's Disease (AD) with Lewy Body variant. In 2019, the U.S. Food and Drug Administration (FDA) bestowed the Breakthrough Device Designation on Amprion for the test's role in diagnosing PD. SYNTap launched commercially in 2021.

About Amprion:

Amprion stands at the forefront in the battle against neurodegenerative disorders with its pioneering seed amplification testing. In response to the demands of an aging global population, the company is dedicated to expediting precision medicine for such disorders. Amprion assists biopharmaceutical partners in identifying new drug candidates and deciphering underlying pathologies through advanced testing methodologies. The cutting-edge seed amplification testing technique was originally conceived by Claudio Soto, Ph.D., Amprion’s Co-Founder and Professor at the University of Texas Health Sciences Center, Houston. It has since been refined and validated by the scientific team within Amprion. The company holds several U.S. and International patents related to SAA methodology and is committed to introducing more biomarker tests that can detect a broad spectrum of early-stage neurodegenerative disorders.

For additional information, you can view Amprion's website here or connect with the company on LinkedIn.

Media Contact: Christina Renfroe 636-352-7883 Email Christina

Jacqueline Champoux 978-933-1389 Email Jacqueline

SOURCE: Amprion

Conclusion

The upcoming AD/PD™ 2024 International Conference in Lisbon promises to be a pivotal moment for the field of neurology, with Amprion at the vanguard showcasing its innovative approaches to diagnosing difficult-to-detect neurodegenerative diseases. Through the wide array of studies and subsequent presentations, scientific discourse will surely be enriched, fostering advancements in the diagnosis and treatment of diseases such as Alzheimer's and Parkinson's. The impact of these advancements is not to be understated, as they hold the promise of altering the trajectory of countless lives faced with the challenges of neurodegenerative conditions.

(Note: This news article incorporates URLs directly into the text to provide readers with additional resources for information and to offer a more integrated reading experience.)